A paradigm shift in rheumatoid arthritis over the past decade

Internal Medicine

Volumn 53, Issue 17, 2014, Pages 1895-1903

  Kaneko, Yuko ^a   Takeuchi, Tsutomu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biological agent; Paradigm shift; Rheumatoid arthritis; Treat to target

Indexed keywords

ADALIMUMAB; B7 ANTIGEN; C REACTIVE PROTEIN; CD86 ANTIGEN; CERTOLIZUMAB PEGOL; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; RHEUMATOID FACTOR; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT;

BIOLOGICAL THERAPY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; PATHOGENESIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYNOVITIS; TREATMENT PLANNING; ARTHRITIS, RHEUMATOID; DISEASE MANAGEMENT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS;

EID: 84906823422     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.53.2834     Document Type: Review

References (74)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 423: 356-361, 2003.
2. van Nies JA, Krabben A, Schoones JW, Huizinga TW, Kloppenburg M, van der Helm-van Mil AH,.What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 73: 861-870, 2014.
3. Scholes M, Smolen JS. Treating rheumatoid arthritis to target: Evidence-based recommendations for enhanced disease management. Reumatol Clin 8: 1-2, 2012.
4. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 365: 2205-2219, 2011.
5. Szekanecz Z, Pakozdi A, Szentpetery A, Besenyei T, Koch AE. Chemokines and angiogenesis in rheumatoid arthritis. Front Biosci (Elite Ed) 1: 44-51, 2009.
6. Polzer K, Baeten D, Soleiman A, et al. Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints. Ann Rheum Dis 67: 1610-1616, 2008.
7. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 85: 307-310, 1996.
8. Hess A, Axmann R, Rech J, et al. Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci USA 108: 3731-3736, 2011.
9. Finckh A, Liang MH, van Herckenrode CM, et al. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 55: 864-872, 2006.
10. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 48: 1771-1774, 2003.
11. Amjadi S, Khanna D, Park GS, et al. Dating the “window of therapeutic opportunity” in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset. J Rheumatol 31: 1686-1692, 2004.
12. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64: 625-639, 2012.
13. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73: 492-509, 2014.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. The America Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324, 1987.
15. Banal F, Dougados M, Combescure C, Gossec L. Sensitivity and specificity of the American College of Rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration: a systematic literature review and meta-analysis. Ann Rheum Dis 68: 1184-1191, 2009.
16. Aletaha D, Neogi T, Silman A, et al. 2010 Rheumatoid arthritis classification criteria: an America college of rhuematology/european league against rheumatism collaborative initiative. Ann Rheum Dis 69: 1580-1588, 2010.
17. Funovits J, Aletaha D, Bykerk V, et al. The 2010 American college of rheumatology/european league against rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. Ann Rheum Dis 69: 1589-1595, 2010.
18. Neogi T, Aletaha D, Silman AJ, et al. The 2010 American college of rheumatology/european league against rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum 62: 2582-2591, 2010.
19. Cader MZ, Filer A, Hazlehurst J, de Pablo P, Buckley CD, et al. Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis:comparison with the 1987 ACR criteria in a very early synovitis cohort. Ann Rheum Dis 70: 949-955, 2011.
20. Kaneko Y, Kuwana M, Kamed H, Takeuchi T. Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) 50: 1268-1274, 2010.
21. Alves C, Luime JJ, van Zeben D, et al. Diagnostic performance of the ACR/EULAR 2010 criteria for rheumatoid arthritis and two diagnostic algorithms in an early arthritis clinic (REACH). Ann Rheum Dis 70: 1645-1647, 2011.
22. Britsemmer K, Ursum J, Gerritsen M, van Tuyl L, van Schaardenburg D. Validation of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: slight improvement over the 1987 ACR criteria. Ann Rheum Dis 70: 1468-1470, 2011.
23. Kawashiri SY, Suzuki T, Okada A, et al. Musculoskeletal ultrasonography assists the diagnostic performance of the 2010 classification criteria for rheumatoid arthritis. Mod Rheumatol 23: 36-43, 2011.
24. van der Linden MM, Knevel R, Huizinga TWJ, van der Helm-van Mil AHM.Classification of rheumatoid arthritis. Comparison of the 1987 America College of Rheumatology criteria and the 2010 American College of Rheumatology/American League Against Rheumatism Criteria. Arthritis Rheum 63: 37-42, 2011.
25. Sakellariou G, Sciré CA, Zambon A, Caporali R, Montecucco C. Performance of the 2010 classification criteria for rheumatoid arthritis: a systematic literature review and a meta-analysis. PLoS One 8: e56528, 2013.
26. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 54: 944-947, 1995.
27. Smolen JS, Aletaha D. What should be our treatment goal in rheumatoid arthritis today? Clin Exp Rheumatol 24 Suppl 43: S-7-S-13, 2006.
28. Pincus T, Gibofsky A, Weinblatt ME. Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. Arthritis Rheum 46: 851-854, 2002.
29. Lansbury J. Quantitation of the activity of rheumatoid arthritis. 5. A method for summation of the systemic indices of rheumatoid activity. Am J Med Sci 232: 300-310, 1956.
30. Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American college of rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64: 640-647, 2012.
31. van der Heijde D, Klareskog L, Boers M, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 64: 1582-1587, 2005.
32. Mäkinen H, Kautiainen H, Hannonen P, et al. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 64: 1410-1413, 2005.
33. Landewé R, van der Heijde D, van der Linden S, et al. Twentyeight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis 65: 637-641, 2006.
34. Felson DT, Smolen JS, Wells G, et al. American college of rheumatology/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70: 404-413, 2011.
35. Thiele K, Huscher D, Bischoff S, et al. Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS 28 remission in unselected patients with rheumatoid arthritis. Ann Rheum Dis 72: 1194-1199, 2013.
36. Zhang B, Combe B, Rincheval N, Felson DT. Validation of ACR/ EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort. Arthritis Res Ther 14: R156, 2012.
37. Kaneko Y, Kondo H, Takeuchi T. American college of rheumatology/european league against rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints. J Rheumatol 40: 1254-1258, 2013.
38. Masri KR, Shaver TS, Shahouri SH, et al. Validity and Reliability Problems with Patient Global as a Component of the ACR/EULAR Remission Criteria as Used in Clinical Practice. J Rheumatol 39: 1139-1145, 2012.
39. Vermeer M, Kuper HH, van der Bijl AH, et al. The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion. Rheumatology (Oxford) 51: 1076-1080, 2012.
40. Havas S, Donner T. Tight control of type 1 diabetes: recommendations for patients. Am Fam Physician 74: 971-978, 2006.
41. Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 75: 894-903, 1995.
42. Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 69: 638-643, 2010.
43. Fransen J, Bernelot Moens H, Speyer I, Van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicenter, cluster randomised control trial. Ann Rheum Dis 64: 1294-1298, 2005.
44. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364: 263-269, 2004.
45. Stenger AA, Van Leeuwen MA, Houtman PM, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 37: 1157-1163, 1998.
46. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66: 1443-1449, 2007.
47. Van Tuyl LH, Lems WF, Voskuyl AE, et al. Tight control and intensifi ed COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 67: 1574-1577, 2008.
48. Edmonds J, Lassere M, Sharp JT. Objectives study in RA (OSRA): a RCT defining the best clinical target for disease activity control in RA. Ann Rheum Dis 66 Suppl II: 325, 2007.
49. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69: 631-637, 2010.
50. Hanoui B, Smolen JS, Aletaha D, et al. Treating rheumatoid arthritis to target:multinational recommendations assessment questionnaire. Ann Rheum Dis 70: 1999-2002, 2011.
51. Haraoui B, Bensen W, Bessette L, et al. Treating rheumatoid arthritis to target: a Canadian physician survey. J Rheumatol 39: 949-953, 2012.
52. Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 6: 644-652, 2010.
53. Abe T, Takeuchi T, Miyasaka N. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J. Rheumatol 33: 37-44, 2006.
54. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50: 1761-69, 2004.
55. Miyasaka N, Investigators TC. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod. Rheumatol 18: 252-262, 2008.
56. Takeuchi T, Matsubara T, Nitobe T, et al. Phase II doseresponse study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod Rheumatol 23: 226-235, 2013.
57. Yamanaka H, Tanaka Y, Sekiguchi N, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol 17: 28-32, 2008.
58. Tanaka Y, Takeuchi T, Inoue E, et al. Retrospective clinical study on the notable efficacy and related factors ofinfliximab therapy in a rheumatoid arthritis management group in Japan: One-year clinical and radiographic outcomes (RECONFIRM-II). Mod Rheumatol 18: 146-152, 2008.
59. Takeuchi T, Tanaka Y, Amano K, et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study. Rheumatology (Oxford) 50: 1908-1915, 2011.
60. Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol 22: 327-338, 2012.
61. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66: 1162-1167, 2007.
62. Takeuchi T, Miyasaka N, Inoue T, et al. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol 19: 478-487, 2009.
63. Lipsky PE, van der Heijde E, St Clair WD, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343: 1594-1602, 2000.
64. Takeuchi T, Miyasaka N, Zang C, et al. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. Mod Rheumatol 23: 623-633, 2013.
65. Tanaka Y, Harigai M, Takeuchi T, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis 71: 817-824, 2012.
66. Takeuchi T, Yamanaka H, Ishiguro N, et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Ann Rheum Dis 73: 536-543, 2014.
67. Yamamoto K, Takeuchi T, Yamanaka H, et al. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Mod Rheumatol (in press).
68. van den Broek M, Lems WF, Allaart CF. BeSt practice: the success of early-targeted treatment in rheumatoid arthritis. Clin Exp Rheumatol 30 (Suppl 73): S35-S38, 2012.
69. Bejarano V, Conaghan PG, Quinn MA, Saleem B, Emery P. Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. Rheumatology(Qxford) 49: 1971-1974, 2009.
70. Vander Cruyssen B, Durez P, Westhovens R, De Keyser F. Sevenyear followup of infliximab therapy in rheumatoid arthritis patients with severe longstanding refractory disease: attrition rate and evolution of disease activity. Arthritis Res Ther 12: R77, 2010.
71. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67: 189-194, 2008.
72. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 36: 898-906, 2009.
73. Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients. Mod Rheumatol (in press).
74. Koike T, Harigai M, Inokuma S, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 41: 15-23, 2014.